Transgenomic company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Market Cap


Stock Price


About Transgenomic

Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for automated high-sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery, and laboratory testing services to the academic and medical research, clinical laboratory, and biopharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Their flagship product is ICE COLD-PCR, which enables use of liquid biopsies for mutation detection.

Transgenomic Headquarter Location

12325 Emmet Street

Omaha, Nebraska, 68164,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Transgenomic

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Transgenomic is included in 2 Expert Collections, including Cancer.



1,284 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Transgenomic Patents

Transgenomic has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors


Application Date


Grant Date



Related Topics

Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors



Latest Transgenomic News

Transgenomic Finalizes Divestment of Its Genetic Assays & Platforms Business Unit

Jun 29, 2020

Transgenomic Finalizes Divestment of Its Genetic Assays & Platforms Business Unit Divestiture to ADSTEC Allows Transgenomic to Focus on Accelerating Commercialization of Its High Potential Multiplexed ICE COLD-PCR™ (MX-ICP) Technology December 01, 2015 07:30 AM Eastern Standard Time OMAHA, Neb.--( BUSINESS WIRE )--Transgenomic, Inc. (NASDAQ: TBIO) today announced that it has completed the divestment of its Genetic Assays & Platforms (GAP) Business Unit to ADSTEC Corporation, and one of its affiliates (ADSTEC). ADSTEC is a privately-held Japanese company that manufactures and sells specialized instruments and reagents for the biotechnology industry. Transgenomic transferred all rights to its GAP products, licenses, technology, know-how and trademarks, along with associated product inventory, to ADSTEC. ADSTEC has assumed the business, financial and human resources commitments of the GAP Business Unit and paid Transgenomic $300,000 for its existing stock and inventory. Paul Kinnon, President and Chief Executive Officer of Transgenomic, commented, “With the closing of this transaction, we have divested our last major legacy business. The aging WAVE product line and geographically diverse customer base of the GAP Business Unit would have required substantial investments to make it competitive. Instead, this divestiture is expected to reduce our expenses by more than $1,000,000 per quarter. Our management and Board of Directors believe our resources will be better invested in growing our high-potential products for molecular diagnostics and precision medicine, powered by our unique ICE COLD-PCR™ technology and growing expertise in developing and commercializing liquid biopsy assays.” ADSTEC’s President, Mr. Tsutomu Kojima, noted, “We believe this is a good deal for both companies. ADSTEC has the infrastructure and resources to revitalize this business unit, which we view as highly complementary to our current efforts. We look forward to the opportunity to work with our new employees to build on the goodwill and customer loyalty that Transgenomic developed during its years of managing this business.” About ADSTEC ADSTEC Corporation, headquartered in Japan and with US and European subsidiaries, including ADS Biotec Inc., is a global leader in the development, manufacture and sale of automated instruments and consumables for use in cytogenetic, pathology and research laboratories. The company’s technology and services enable its customers to increase productivity and throughput while maintaining a high degree of quality and consistency. With the acquisition of the Genetic Assays & Platforms (GAP) Business Unit of Transgenomic, ADSTEC has a truly global presence with development, sales and support operations on three continents, and users in over 30 countries. With a company-wide commitment to quality and value, the company serves professionals and laboratories performing diagnostic analysis in the areas of cytogenetics, pathology and molecular genetic analysis. For more information, visit . About Transgenomic Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ technology and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These forward-looking statements include statements relating to the anticipated effects of the sale of the GAP Business Unit and Transgenomic’s anticipated investment in its other technologies. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, Transgenomic claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Transgenomic Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Transgenomic Rank

  • When was Transgenomic founded?

    Transgenomic was founded in 1997.

  • Where is Transgenomic's headquarters?

    Transgenomic's headquarters is located at 12325 Emmet Street, Omaha.

  • What is Transgenomic's latest funding round?

    Transgenomic's latest funding round is PIPE.

  • How much did Transgenomic raise?

    Transgenomic raised a total of $10M.

  • Who are the investors of Transgenomic?

    Investors of Transgenomic include Knott Partners, SF Capital Group, Iroquois Capital Group, Omicron Capital, Dorset Management Corporation and 6 more.

  • Who are Transgenomic's competitors?

    Competitors of Transgenomic include BioDelivery Sciences International, Flexion Therapeutics, Gliknik, OpGen, Everist Health, Life Technologies Corporation, Helicos BioSciences, Expression Analysis, Lipomics Technologies, Caliper Life Sciences and 16 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.


SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.


Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.


QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

CAPE Technologies

CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.